G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06 Julho 2023 - 5:15PM
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology
company, today announced the grant of inducement stock options
exercisable for 5,600 shares of G1’s common stock and 2,800
restricted stock units (RSUs) to two hired employees under the
Amended and Restated G1 Therapeutics, Inc. 2021 Inducement Equity
Incentive Plan (the “Amended and Restated 2021 Plan”). These equity
awards were granted as an inducement material to the new employee
becoming an employee of G1 in accordance with Nasdaq Listing Rule
5635(c)(4).
The Amended and Restated 2021 Plan is used exclusively for the
grant of equity awards to individuals who were not previously
employees of G1 (or following a bona fide period of
non-employment), as an inducement material to such individual’s
entering into employment with G1, pursuant to Rule 5635(c)(4) of
the Nasdaq Listing Rules.
The stock options are exercisable at a price of $2.47 per share,
the closing price of G1’s common stock on July 3, 2023, the grant
date. The stock options have up to a ten-year term and vest over
four years, with 25% of the award vesting on the first anniversary
of the employee’s employment, and as to an additional 1/48th of the
shares monthly thereafter, subject to continued service through the
applicable vesting dates (subject to the terms and conditions of
the stock option agreement covering the grant). The RSUs have a
four-year term, with 25% of the award vesting on the first
anniversary of the grant date, and the remainder vesting 12.5%
semi-annually over the remaining three years, subject to continued
service through the applicable vesting dates (subject to the terms
and conditions of the RSU agreement covering the grant). The stock
options and RSUs are subject to the terms and conditions of the
Amended and Restated 2021 Plan.
About G1 TherapeuticsG1 Therapeutics, Inc. is a
commercial-stage biopharmaceutical company focused on the
development and commercialization of next generation therapies that
improve the lives of those affected by cancer, including the
Company’s first commercial product, COSELA® (trilaciclib). G1 has a
deep clinical pipeline and is executing a development plan
evaluating trilaciclib in a variety of solid tumors, including
breast, lung, and bladder cancers. G1 Therapeutics is based in
Research Triangle Park, N.C. For additional information, please
visit www.g1therapeutics.com and follow us on Twitter
@G1Therapeutics.
G1 Therapeutics® and the G1 Therapeutics logo and COSELA® and
the COSELA logo are trademarks of G1 Therapeutics, Inc.
Contact:
Will RobertsG1 Therapeutics, Inc.Vice President, Investor
Relations and Corporate Communications(919) 907-1944
wroberts@g1therapeutics.com
G1 Therapeutics (NASDAQ:GTHX)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
G1 Therapeutics (NASDAQ:GTHX)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024